[Evaluation of a new non-steroidal anti-inflammatory agent in degenerative osteo-articular pathology].
Cinnoxicam (Sinartrol) was used in 20 patients with inflammatory-degenerative osteoarticular diseases. The new NSAID was administered by oral or rectal route once daily for a standard 15-day period. The treatment brought about a significant improvement in the clinical variables considered (spontaneous pain at rest and on movement and functional limitation), which was observed within a few days of starting therapy. Tolerance was good, only a few slight side-effects having been reported.
Caniggia
M
M
Clinica Ortopedica, Università degli Studi, Siena.
Morreale
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007719:Knee Joint; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D015207:Osteoarthritis, Hip / Q000188:drug therapy; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013122:Spinal Diseases / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C057291:piroxicam cinnamate
Valutazione di un nuovo antiflogistico non steroideo nella patologia degenerativa osteo-articolare.